Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
Abstract Background In recent years, many studies have illustrated that the neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor of metastatic castration-resistant prostate cancer (mCRPC), but their conclusions are controversial. The aim of this study was to assess the prognostic value of the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-024-01685-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571218294734848 |
|---|---|
| author | Ying Zhang Xiao Zhou Ran Xu Guangcheng Luo Xinjun Wang |
| author_facet | Ying Zhang Xiao Zhou Ran Xu Guangcheng Luo Xinjun Wang |
| author_sort | Ying Zhang |
| collection | DOAJ |
| description | Abstract Background In recent years, many studies have illustrated that the neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor of metastatic castration-resistant prostate cancer (mCRPC), but their conclusions are controversial. The aim of this study was to assess the prognostic value of the NLR in patients with mCRPC treated with docetaxel-based chemotherapy. Methods Database searches were conducted in PubMed, EMBASE and the Cochrane Library to retrieve relevant published English-language literature up to 20 February 2023. RevMan 5.4.1 was used to summarize the hazard ratio (HR) and its 95% confidence interval (CI) for overall survival (OS) and progression-free survival (PFS) with subgroup analysis. Finally, Stata software was adopted for sensitivity analysis, and Egger’s test was used to calculate the results of stability to determine whether there was publication bias. Results A total of 1,983 mCRPC patients from 14 retrospective cohort studies were included in this meta-analysis. The combined results showed that elevated NLR was significantly associated with worse OS (HR = 1.86, 95% CI: 1.55–2.23, P < 0.00001) and PFS (HR = 1.96 (95% CI: 1.52–2.53), P < 0.00001) in patients with mCRPC treated with docetaxel-based therapy. For subgroup analysis of high NLR, studies performed in Asia and cutoff value > 3 were associated with poorer OS, while cutoff values > 3 were associated with poorer PFS. Conclusion Our results suggest that the neutrophil-to-lymphocyte ratio may be a prognostic factor in patients with mCPRC with docetaxel-based chemotherapy. |
| format | Article |
| id | doaj-art-1cd8be705b024d56bcdaf5cdbf2e2999 |
| institution | Kabale University |
| issn | 1471-2490 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj-art-1cd8be705b024d56bcdaf5cdbf2e29992025-02-02T12:44:22ZengBMCBMC Urology1471-24902025-01-0125111110.1186/s12894-024-01685-4Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysisYing Zhang0Xiao Zhou1Ran Xu2Guangcheng Luo3Xinjun Wang4The School of Clinical Medicine, Fujian Medical UniversityDepartment of Urology, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen UniversityDepartment of Urology, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen UniversityThe School of Clinical Medicine, Fujian Medical UniversityThe School of Clinical Medicine, Fujian Medical UniversityAbstract Background In recent years, many studies have illustrated that the neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor of metastatic castration-resistant prostate cancer (mCRPC), but their conclusions are controversial. The aim of this study was to assess the prognostic value of the NLR in patients with mCRPC treated with docetaxel-based chemotherapy. Methods Database searches were conducted in PubMed, EMBASE and the Cochrane Library to retrieve relevant published English-language literature up to 20 February 2023. RevMan 5.4.1 was used to summarize the hazard ratio (HR) and its 95% confidence interval (CI) for overall survival (OS) and progression-free survival (PFS) with subgroup analysis. Finally, Stata software was adopted for sensitivity analysis, and Egger’s test was used to calculate the results of stability to determine whether there was publication bias. Results A total of 1,983 mCRPC patients from 14 retrospective cohort studies were included in this meta-analysis. The combined results showed that elevated NLR was significantly associated with worse OS (HR = 1.86, 95% CI: 1.55–2.23, P < 0.00001) and PFS (HR = 1.96 (95% CI: 1.52–2.53), P < 0.00001) in patients with mCRPC treated with docetaxel-based therapy. For subgroup analysis of high NLR, studies performed in Asia and cutoff value > 3 were associated with poorer OS, while cutoff values > 3 were associated with poorer PFS. Conclusion Our results suggest that the neutrophil-to-lymphocyte ratio may be a prognostic factor in patients with mCPRC with docetaxel-based chemotherapy.https://doi.org/10.1186/s12894-024-01685-4Neutrophil-to-lymphocyte ratioDocetaxelmCPRCPrognosis |
| spellingShingle | Ying Zhang Xiao Zhou Ran Xu Guangcheng Luo Xinjun Wang Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis BMC Urology Neutrophil-to-lymphocyte ratio Docetaxel mCPRC Prognosis |
| title | Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis |
| title_full | Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis |
| title_fullStr | Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis |
| title_full_unstemmed | Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis |
| title_short | Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis |
| title_sort | neutrophil to lymphocyte ratio as a prognostic factor in patients with castration resistant prostate cancer treated with docetaxel based chemotherapy a meta analysis |
| topic | Neutrophil-to-lymphocyte ratio Docetaxel mCPRC Prognosis |
| url | https://doi.org/10.1186/s12894-024-01685-4 |
| work_keys_str_mv | AT yingzhang neutrophiltolymphocyteratioasaprognosticfactorinpatientswithcastrationresistantprostatecancertreatedwithdocetaxelbasedchemotherapyametaanalysis AT xiaozhou neutrophiltolymphocyteratioasaprognosticfactorinpatientswithcastrationresistantprostatecancertreatedwithdocetaxelbasedchemotherapyametaanalysis AT ranxu neutrophiltolymphocyteratioasaprognosticfactorinpatientswithcastrationresistantprostatecancertreatedwithdocetaxelbasedchemotherapyametaanalysis AT guangchengluo neutrophiltolymphocyteratioasaprognosticfactorinpatientswithcastrationresistantprostatecancertreatedwithdocetaxelbasedchemotherapyametaanalysis AT xinjunwang neutrophiltolymphocyteratioasaprognosticfactorinpatientswithcastrationresistantprostatecancertreatedwithdocetaxelbasedchemotherapyametaanalysis |